artJazz The European Commission (EC) approved Novartis (NYSE:NVS) Pluvicto to treat certain patients with advanced prostate cancer. The radioligand therapy was approved in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition to treat adult patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer […]
Friday, May 23, 2025
Breaking News